Definitive Healthcare (NASDAQ:DH) Releases FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.180-0.200 for the period, compared to the consensus EPS estimate of 0.160. The company issued revenue guidance of $220.0 million-$222.0 million, compared to the consensus revenue estimate of $223.6 million. Definitive Healthcare also updated its Q3 2026 guidance to 0.040-0.050 EPS.

Definitive Healthcare Stock Down 2.1%

Shares of NASDAQ DH traded down $0.01 during trading on Monday, hitting $0.70. 172,029 shares of the company traded hands, compared to its average volume of 358,377. The firm has a market capitalization of $73.71 million, a price-to-earnings ratio of -0.43, a P/E/G ratio of 11.51 and a beta of 1.35. The business’s fifty day moving average is $0.78 and its 200 day moving average is $1.12. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. Definitive Healthcare has a fifty-two week low of $0.62 and a fifty-two week high of $4.35.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.The company had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Equities research analysts predict that Definitive Healthcare will post 0.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

DH has been the topic of several recent research reports. Robert W. Baird set a $1.10 price target on Definitive Healthcare in a report on Friday, May 8th. Bank of America reaffirmed an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research report on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Finally, Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $1.88.

Institutional Trading of Definitive Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC bought a new stake in Definitive Healthcare in the 4th quarter worth about $92,000. Jain Global LLC bought a new position in shares of Definitive Healthcare during the 4th quarter worth approximately $75,000. PharVision Advisers LLC bought a new position in shares of Definitive Healthcare in the third quarter valued at approximately $120,000. BNP Paribas Financial Markets grew its holdings in shares of Definitive Healthcare by 32.9% in the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after acquiring an additional 4,407 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Definitive Healthcare during the third quarter valued at approximately $155,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.